Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07694700 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Colistin and Meropenem Versus Amikacin and Meropenem for MDR Gram Negative Bacteria Regarding Efficacy and Safety.

Study acronym: MDR
StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 14, 2026 (before its estimated August 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion pushed from Jun 30, 2026 to Aug 30, 2026
    • Study completion pushed from Jun 30, 2026 to Sep 30, 2026
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Objective of this study is to compare the efficacy and safety between combination of colistin and meropenem and combination of amikacin and meropenem for multi-drug-resistant gram-negative bacteria in Intensive Care Unit. In Beni- Suef University Hospital.
Trial Details
NCT Number NCT07694700
Lead Sponsor Beni-Suef University
Conditions
(from sponsor)		 MDR Bacteria
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov